Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia

被引:105
作者
Gobbi, H
Dupont, WD
Simpson, JF
Plummer, WD
Schuyler, PA
Olson, SJ
Arteaga, CL
Page, DL
机构
[1] Vanderbilt Univ, Med Ctr, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol, Nashville, TN 37232 USA
[3] Univ Fed Minas Gerais, Sch Med, Dept Anat Pathol, Belo Horizonte, MG, Brazil
[4] Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA
关键词
D O I
10.1093/jnci/91.24.2096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Transforming growth factors-beta (TGF-beta s) regulate mammary epitheIiaI cell division. Loss of expression of TGF-beta receptor II (TGF-beta-RII) is related to cell proliferation and tumor progression. Breast epithelial hyperplastic lesions lacking atypia (EHLA) are associated with a mild elevation in breast cancer risk, We investigated the expression of TGF-beta-RII in EHLA and the risk of subsequent invasive breast cancer. Methods: We conducted a nested case-control study of women with biopsy-confirmed EHLA who did not have a history of breast cancer or atypical hyperplasia of the breast. Case patients (n = 54) who subsequently developed invasive breast cancer were matched with control patients (n = 115) who did not. Formalin-fixed, paraffin-embedded sections of breast biopsy specimens of all 169 patients with EHLA were studied by immunohistochemical analysis with antibodies against TGF-beta-RII, All P values are two-sided. Results: Women with breast EHLA and 25%-75% TGF-beta-RII-positive cells or less than 25% TGF-beta-RII-positive cells had odds ratios of invasive breast cancer of 1.98 (95% confidence interval [CI] = 0.95-4.1) or 3.41 (95% CI = 1.2-10.0), respectively (P for trend = .008). These risks are calculated with respect to women with EHLA that had greater than 75% TGF-beta-RII expression. Women with a heterogeneous pattern of TGF-beta-RII expression in their normal breast lobular units and either greater than 75%, 25%-75%, or less than 25% positive cells in their EHLA had odds ratios for breast cancer risk of 0.742 (95% CI = 0.3-1.8), 2.85 (95% CI = 1.1-7.1), or 3.55 (95% CI = 1.0-10.0), respectively (P for trend =.003). These risks are relative to women with a homogeneous pattern of expression in their normal lobular units and greater than 75% positive cells in their EHLA. Conclusion: This study indicates that loss of TGF-beta-RII expression in epithelial cells of EHLA is associated with increased risk of invasive breast cancer.
引用
收藏
页码:2096 / 2101
页数:6
相关论文
共 52 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]   Biomarkers in benign breast disease: Risk factors for breast cancer [J].
Allred, DC ;
Hilsenbeck, SG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17) :1247-1248
[3]   Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development [J].
Amendt, C ;
Schirmacher, P ;
Weber, H ;
Blessing, M .
ONCOGENE, 1998, 17 (01) :25-34
[4]   The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology [J].
Arteaga, CL ;
Dugger, TC ;
Hurd, SD .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) :49-56
[5]  
ARTEAGA CL, 1988, CANCER RES, V48, P3898
[6]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[7]  
Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009
[8]  
Breslow NE, 1980, STAT METHODS CANC RE, V1, DOI DOI 10.1097/00002030-199912240-00009
[9]  
Breslow NE, 1987, STAT METHODS CANC RE, VII
[10]   REDUCED SURFACE EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR-TYPE-II IN MITOGEN-ACTIVATED T-CELLS FROM SEZARY PATIENTS [J].
CAPOCASALE, RJ ;
LAMB, RJ ;
VONDERHEID, EC ;
FOX, FE ;
ROOK, AH ;
NOWELL, PC ;
MOOREN, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5501-5505